THE JOURNAL OF BIOLOGICAL CHEMISTRY
© 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Vol. 276, No. 43, Issue of October 26, pp. 40175–40182, 2001
Printed in U.S.A.
Cloning and Characterization of an Alternatively Spliced Form of
SR Protein Kinase 1 That Interacts Specifically with Scaffold
Attachment Factor-B*
Received for publication, May 24, 2001, and in revised form, July 20, 2001
Published, JBC Papers in Press, August 16, 2001, DOI 10.1074/jbc.M104755200
Eleni Nikolakaki‡§, Rachel Kohen¶, Annette M. Hartmann储, Stefan Stamm**, Elena Georgatsou¶,
and Thomas Giannakouros‡
From the ‡Laboratory of Biochemistry, School of Chemistry, The Aristotelian University of Thessaloniki, Thessaloniki
54006, Greece, the ¶Laboratory of Biochemistry, Medical School, University of Thessaly, Larissa 41222, Greece, the
储Ludwig Maximilian University, Nussbaumstrasse 7, München 80336, Germany, and the **Institute of Biochemistry,
University of Erlangen-Nurenberg, Fahrstrasse 17, Erlangen 91054, Germany
Serine/arginine (SR1) protein kinases represent a novel
* This work was supported by grants from the Greek Secretariat of
Research and Technology (⌸ENE⌬ 1999 to T. G. and E. G.), from the
Greek Ministry of Education (⌸.⌺.E to E. G.), and from the Deutsche
Forschungsgemeinschaft (SFB 473) and the Johannes and Frieda
Marohn Stiftung (to S. S.). The costs of publication of this article were
defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted
to the GenBankTM/EBI Data Bank with accession number(s) AJ318054
and AJ224115.
§ To whom correspondence should be addressed: Laboratory of Biochemistry, School of Chemistry, Aristotelian University of Thessaloniki, Thessaloniki 54006, Greece. Tel.: 30-31-997726; Fax: 30-31997689; E-mail: nikol@ccf.auth.gr.
1
The abbreviations used are: SR, serine/arginine; SRPK serine/arginine protein kinase; SC, synthetic complete; LBR, lamin B receptor;
SAF-B, scaffold attachment factor-B; S/MAR, scaffold/matrix attachment regions; bp, base pair(s); RT-PCR, reverse transcription-polymerase chain reaction; GST, glutathione S-transferase; CMV, cytomegalovirus; GFP, green fluorescence protein; AT, 3-aminotriazole;
PMSF, phenylmethylsulfonyl fluoride; PAGE, polyacrylamide gel
electrophoresis.
This paper is available on line at http://www.jbc.org
class of enzymes that specifically modify SR or RS dipeptide
motifs. To date, at least nine distinct genes encoding SR
protein kinases have been identified in the genomes of mammals (human SRPK1, GenBank娂 accession number U09564;
human SRPK2, U88666A; mouse SRPK1, AJ224115; mouse
SRPK2, B006036), yeast (Saccharomyces cerevisiae Sky1,
S55098; Schizosaccharomyces pombe Dsk1, D13447), fruit fly
(Drosophila SRPK1, AF01149), nematode (Caenorhabditis
elegans SPK-1, AF241656), and plants (Arabidopsis thaliana
SRPK1, AJ292978).
Mammalian SRPK1 and SRPK2, which are highly related in
sequence, kinase activity, and substrate specificity, were initially purified and cloned on the basis of their ability to phosphorylate members of the SR family of splicing factors in vitro
and mediate splicing factor redistribution during the cell cycle
(1– 4). SR proteins themselves constitute a highly conserved
protein family that is intimately involved in the regulation of
pre-mRNA splicing and other steps of RNA metabolism (for
reviews, see Refs. 5–7). Biochemical studies demonstrated that
SR proteins are required at multiple steps in the assembly of
the spliceosome, the dynamic RNA-protein complex that catalyzes intron removal (8 –10). Because RS domains are known to
participate in protein-protein and protein-RNA interactions
during spliceosome assembly, phosphorylation of these domains can modulate interactions involving SR proteins and is,
therefore, essential for their function in constitutive splicing (3,
11, 12). Furthermore, phosphorylation of SR proteins leads to
their release from nuclear speckles, in which they are concentrated to active sites of transcription in the nucleoplasm (1, 3,
13–15). Because changes in the intranuclear SR protein concentration play a critical role in determining which of the
competing splice sites are selected, phosphorylation can also
indirectly control alternative splice site selection (16 –20). Finally, it has been proposed that the formation of complexes
between SF2/ASF and SRPKs may modulate the subcellular
distribution of SF2/ASF (21).
Yet, the lack both of authentic SR proteins in the yeast
genome and of alternative mRNA splicing in yeast suggests
that these kinases play roles in the regulation of cellular processes in addition to that of mRNA splicing. Indeed, genetic
analyses have implicated Dsk1, which is the fission yeast homologue of SRPK1 in the regulation of chromosome segregation
at the metaphase/anaphase transition (22). Furthermore, one
of the endogenous substrates of Sky1p, in S. cerevisiae, is the
RNA binding protein Npl3p, which has been implicated in
mRNA transport (23). Sky1p was found to regulate nuclear
import of Npl3p by promoting the interaction between Npl3p
40175
Downloaded from www.jbc.org by guest, on February 19, 2013
Serine/arginine protein kinases have been conserved
throughout evolution and are thought to play important
roles in the regulation of mRNA processing, nuclear import, germline development, polyamine transport, and
ion homeostasis. Human SRPK1, which was first identified as a kinase specific for the SR family of splicing
factors, is located on chromosome 6p21.2-p21.3. We report here the cloning and characterization of SRPK1a,
which is encoded by an alternatively processed transcript derived from the SRPK1 gene. SRPK1a contains
an insertion of 171 amino acids at its NH2-terminal domain and is similar to SRPK1 in substrate specificity
and subcellular localization. Moreover, both isoforms
can induce alternative splicing of human tau exon 10 in
transfected cells. Using the yeast two-hybrid assay, we
found that the extended NH2-terminal domain of
SRPK1a interacts with Scaffold Attachment Factor-B, a
nuclear scaffold-associated protein. Confirmation of
this interaction was provided by in vitro binding assays,
as well as by co-immunoprecipitation from 293T cells
doubly transfected with SRPK1a and SAF-B. Our studies
suggest that different SRPK family members are
uniquely regulated and targeted and thus the multiple
SRPK kinases present in higher eukaryotes may perform specialized and differentiable functions.
40176
Cloning and Characterization of SRPK1a
MATERIALS AND METHODS
Cloning of Human SRPK1a—A Lambda ZAP Express human testis
cDNA library (Stratagene, La Jolla, CA) was screened using a 617-bp
fragment, comprising part of the sequence of human SRPK1 (1) (nucleotides 262– 879, starting from ATG; for details see Ref. 27). 5 ⫻ 105
plaques were screened by hybridization of Hybond filters (Amersham
Pharmacia Biotech) using standard procedures (31) and yielded ten
positive clones. One of the clones corresponded to full-length SRPK1.
Two of the clones were identical to SRPK but contained an insertion of
513 bp between AAA (encoding lysine, the fourth amino acid of SRPK1)
and GTG (encoding valine, the fifth amino acid of SRPK1). The sequence of both strands was determined using specific oligonucleotide
primers and by a series of nested deletions and unidirectional exonuclease III digestion according to the manufacturer’s instructions (double-stranded Nested deletion kit, Amersham Pharmacia Biotech, Uppsala, Sweden). The EMBL data bank accession number for SRPK1a is
AJ318054.
Northern Blot Hybridization—Human multiple tissue I and II Northern blot filters were purchased from CLONTECH Laboratories (Palo
Alto, CA) and processed as previously described (27). A cDNA of 860 bp,
comprising nucleotides 1– 860 of the sequence of mouse SRPK1 (EMBL
data bank accession number AJ224115; see also Ref. 27), and a PCR
fragment of 528 bp, comprising nucleotides 1–528 of the coding region
of human SRPK1a, were used as probes for SRPK1 and SRPK1a,
respectively. The 860-bp mouse fragment is 92% identical, at the DNA
level, (98% at the protein level) to the respective human fragment.
RT-PCR Analysis—RT-PCR analysis was performed using the Titan
One Tube RT-PCR system (Roche Molecular Biochemicals, Mannheim
D-68298, Germany) as per the manufacturer’s instructions. Total RNA
from human testis, provided from CLONTECH laboratories, was used
as template. Two micrograms of testis RNA was initially denatured at
94 °C for 1 min and then incubated, for first-strand cDNA synthesis,
with 10 pmol of antisense primer (5⬘-CTTCCTGCTCTGGTAGATCAC3⬘) at 55 °C for 35 min. The following sense primer (10 pmol) was used
for PCR amplification: 5⬘-GGTCTCACCATGGAGCGGAAA-3⬘. PCR
conditions were: denaturation at 94 °C for 2 min, followed by 40 cycles:
30-s denaturation at 94 °C, annealing at 58 °C for 30 s, extension at
68 °C for 40 s, and a final extension at 68 °C for 10 min. Amplified
products were resolved by electrophoresis through 1% agarose gel and
ethidium bromide staining.
Plasmids, Expression of Proteins, and Antibodies—The pGEX-2T
bacterial expression vector (Amersham Pharmacia Biotech) was used to
express human SRPK1 (27, 28) and the NH2-terminal domain of
SRPK1a (amino acids 1–176; construct termed GST-SRPK1aNt) fused
with glutathione S-transferase (GST) in Escherichia coli. To subclone
the NH2-terminal domain of SRPK1a into pGEX-2T, two primers
(sense: 5⬘-AGTAGGATCCATGGAGCGGAAAGGTGAGCGG-3⬘, containing a BamHI site; antisense: 5⬘-CTAGAAGCTTCACTGCAGGAGAGAGGGATGG-3⬘) were used to amplify a DNA fragment, comprising nucleotides 1–528 of the coding region of SRPK1a, by
polymerase chain reaction. PCR was performed as described (29) but
with the addition of 10% Me2SO. The PCR fragment was digested with
BamHI, repurified, and cloned into the BamHI and SmaI sites of
pGEX-2T. Wild-type and specifically altered forms of LBR protein were
prepared as GST fusion proteins as previously described (29). Briefly,
wtNt: contains the NH2-terminal domain of LBR (amino acids 1–205);
⌬RSNt: contains the NH2-terminal domain of LBR but lacks the RS
motifs (amino acids 75– 84; 75RSRSRSRSRS84); wtNtG78, wtNtA80, wtNtA82, and wtNtA84: fusion proteins identical to wtNt except that in
each case Ser78, Ser80, Ser82, or Ser84 was mutated to Gly or Ala.
Full-length SRPK1 and SRPK1a were also subcloned into the p-FLAGCMV-2 (Eastman Kodak) vector and expressed in 293T cells with a
FLAG tag fused at their NH2 termini. For this purpose oligonucleotides
corresponding to the 5⬘- and 3⬘-complementary coding regions of human
SRPK1 and SRPK1a with additional EcoRI sites at the 5⬘- and 3⬘-ends,
respectively, were prepared (SRPK1, sense: 5⬘-CGGGAATTCTATGGAGCGGAAAGTGCTTGCG-3⬘, antisense: 5⬘-CGAGAATTCCCGGAGTTAAGCCAAGGGTGCCG-3⬘; SRPK1a, sense: 5⬘-CGGGAATTCTATGGAGCGGAAAGGTGAGCGG-3⬘, antisense: 5⬘-CGAGAATTCCCGGAGTTAAGCCAAGGGTGCCG-3⬘), and PCR was performed. The products
were digested with EcoRI, repurified, and cloned into the EcoRI site of
p-FLAG-CMV-2 in the correct orientation. Rat SAF-B-PC encoding the
COOH-terminal part of rat SAF-B (starting from nucleotide 1746 of the
rat SAF-B sequence; EMBL data bank accession number AF056324)
was expressed as a GST fusion protein or subcloned into the pEGFP-C2
vector (CLONTECH) and expressed in 293T cells with green fluorescence protein (GFP) fused at its NH2 terminus as previously described
(32).
Polyclonal antibodies against SRPK1/SRPK1a and specifically
against SRPK1a were produced by injecting GST-SRPK1 and GSTSRPK1aNt into rabbits as described previously (33). The M5 anti-FLAG
monoclonal antibody was a kind gift of George Mosialos (Biomedical
Sciences Research Center Al. Fleming, Vari, Attiki), whereas the antiGFP monoclonal antibody was obtained from Roche Molecular
Biochemicals.
Yeast Two-hybrid Screen—A 528-bp fragment coding for the NH2terminal domain of SRPK1a (SRPK1aNt; see above) was amplified by
PCR (sense primer: 5⬘-CTGGAATTCATGGAGCGGAAAGGTGAGCGG3⬘; antisense primer: 5⬘-CTAGAAGCTTCACTGCAGGAGAGAGGGATGG-3⬘), digested with BamHI, and cloned into the BamHI and SmaI
sites of pGBT9 (CLONTECH) in-frame with the GAL4 DNA binding
domain. S. cerevisiae strain pJ69-4A (MATa trp1–901 leu2–3, 112
ura3–52 his3–200 gal4⌬ gal80⌬ LYS2::GAL1-HIS3 GAL2-ADE2
met2::GAL7-lacZ) (34) was co-transformed with pGBT9-SRPK1aNt and
an equimolar mixture of E9.5 and E10.5 mouse embryonic cDNA libraries constructed in the pVP16 fusion vector (35). Positive clones were
selected on SC (synthetic complete) minus Trp, Leu, His medium (36)
containing 11.25 M Ade and 3 mM AT (3-amino triazole). The positive
pVP16-derived plasmids isolated in this screen were rescued and used
to again co-transform yeast strain pJ69-4A with pGBT9-SRPK1aNt or
pGBT9-SRPK1 to confirm and test the specificity of the interactions.
The coding region of SRPK1 was amplified by PCR (sense primer:
5⬘-GTAGAATTCATGGAGCGGAAAGTGCTTGCG-3⬘; antisense
primer: 5⬘-TAGGAATTCGGAGTTAAGCCAAGGGTGCCG-3⬘), digested
with EcoRI, and cloned into the EcoRI site of pGBT9 in the correct
orientation.
Cell Culture, Western Blotting, and Immunoprecipitation—Human
293T cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v/v) fetal calf serum and antibiotics. 5 ⫻ 105
cells (⬃50% confluent) were transfected with 5 g of p-FLAG-CMV-2SRPK1 or p-FLAG-CMV-2-SRPK1a DNA using the calcium phosphate
method (37). Total amounts of plasmid DNA were made up to 20 g
with pcDNA3 (Invitrogen). After 16 h the medium was changed and the
Downloaded from www.jbc.org by guest, on February 19, 2013
and its nuclear import receptor Mtr10p (24). In a recent report
it was also demonstrated that Sky1p is a key regulator of
polyamine transport in S. cerevisiae (25). Sky1 disruption in
yeast cells resulted in dramatically reduced uptake of spermine, spermidine, or putrescine. Data presented in the same
report suggest that Sky1p is also involved in regulating ion
homeostasis.
Further support for the hypothesis that SRPKs have a
broader regulatory role was obtained with the finding that the
C. elegans family member spk-1 is predominantly expressed in
germ cells and is required for germline development in C.
elegans (26). In line with the above observations we have recently shown that SRPK1 is highly expressed in human and
mouse testis and that the enzyme phosphorylates protamine 1
in an efficient and highly specific manner (27). SRPK1 also has
other additional substrates, besides the SR family of splicing
factors, such as the Lamin B Receptor (LBR), an integral protein of the inner nuclear membrane, that contains a stretch of
RS repeats at its nucleoplasmic NH2-terminal domain (28, 29).
Here we report the cloning and characterization of a novel
SRPK1 gene product, named SRPK1a, that contains an insertion of 171 amino acids at its NH2-terminal domain. The two
SRPK isoforms are nearly identical in terms of substrate specificity and subcellular localization and in their ability to induce
alternative splicing in transfected cells. Furthermore, they
were similarly expressed in various human tissues, although
the level of expression of SRPK1a was significantly lower than
that of SRPK1. Yet, using the yeast two-hybrid assay we found
that, unlike SRPK1, SRPK1a interacts, via its NH2-terminal
domain, with SAF-B, a well characterized S/MAR binding protein. The so-called S/MARs (for Scaffold/Matrix Attachment
Regions) are specialized DNA elements that mediate the attachment of chromatin to the nuclear scaffold and have been
found in all eukaryotic organisms investigated (for review see
Ref. 30). The implications of this interaction are discussed
below.
Cloning and Characterization of SRPK1a
40177
RESULTS
In our previous reports we used a PCR approach to reclone
the SRPK1 cDNA to examine its relationship with a previously
identified LBR kinase (28, 29) and identify novel substrates
besides the SR family of splicing factors (27). In this respect we
screened a Lambda ZAP Express human testis cDNA library,
at high stringency, using as a probe a 617-bp PCR fragment
comprising nucleotides 262– 879 of the sequence of human
SRPK1 (for details see Ref. 27). We isolated three full-length
cDNA sequences corresponding to SRPK1. However, one of the
clones contained an insertion of 513 bp between AAA (encoding
lysine, the fourth amino acid of SRPK1) and GTG (encoding
valine, the fifth amino acid of SRPK1), which is absent from the
known sequence of SRPK1 (see Figs. 1 and 2). Because it is well
Downloaded from www.jbc.org by guest, on February 19, 2013
cells were incubated for another 24 h. Cells were lysed with 200 l of 1%
Triton buffer (1% Triton X-100, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
10 g/ml aprotinin, and 1 mM PMSF) for 30 min on ice. Whole cell
extracts were clarified by centrifugation for 15 min in a microcentrifuge, and the protein concentration was determined by the method of
Bradford (38). One hundred and fifty micrograms of each lysate was
supplemented with the appropriate volume of 5⫻ sample electrophoresis buffer and analyzed on 10% SDS-PAGE. Western blotting was
performed with the M5 anti-FLAG monoclonal antibody, an alkaline
phosphatase-coupled goat anti-mouse secondary antibody, and 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium substrate. For
immunoprecipitation 100 g of each extract was incubated with 1 l of
the M5 anti-FLAG monoclonal antibody or with 5 l of the anti-SRPK1
or the anti-SRPK1a polyclonal antibodies for 3 h on ice. Twenty microliters of protein G beads (for the monoclonal antibody) or protein A
beads (for the polyclonal antibodies) was added and incubated overnight on ice. Antigen-antibody complexes were collected by centrifugation and were washed three times with lysis buffer. In vitro phosphorylation assays were performed on beads as described previously (29)
using as substrates wild-type and specifically altered forms of LBR
protein (see above) and recombinant ASF/SF2 (kindly provided by
Jamal Tazi, Institut de Génétique Moléculaire de Montpellier, UMR
5535, CNRS). The same procedure was followed for immunoprecipitation from rat testis cytosol.
Cells co-transfected with plasmid DNA encoding GFP-SAF-B-PC and
FLAG-SRPK1 or FLAG-SRPK1a were lysed in 200 l of radioimmune
precipitation buffer (1% Nonidet P-40, 1% sodium deoxycholate, 0.1%
SDS, 150 mM NaCl, 10 mM sodium phosphate, pH 7.2, 2 mM EDTA, 10
g/ml aprotinin, and 1 mM PMSF). One hundred microliters of the
supernatants, following centrifugation, was diluted 4-fold in radioimmune precipitation rescue buffer (10 mM sodium phosphate, pH 7.2, 20
mM NaCl, 10 g/ml aprotinin, and 1 mM PMSF) and immunoprecipitations were performed overnight at 4 °C, under shaking, using 3 l of
anti-GFP antibody and 20 l of protein G-Sepharose. The beads were
washed three times in a buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1
mM EDTA, 10% glycerol, 0.1% Triton X-100, 10 g/ml aprotinin, and 1
mM PMSF) and resuspended in 30 l of SDS sample buffer. The bound
proteins were subsequently analyzed on 10% SDS-PAGE followed by
Western blotting using the M5 anti-FLAG monoclonal antibody.
GST Pull-down Experiments—GST-SAF-B (⬃3– 4 g) immobilized
on glutathione-Sepharose beads was incubated with 50 l of cell extract, derived from 293T cells transfected with plasmid DNA encoding
either FLAG-SRPK1 or FLAG-SRPK1a, in phosphate-buffered saline
buffer (20 mM phosphate buffer, pH 7.4, 150 mM NaCl, 0.5 mM PMSF)
in a total volume of 0.5 ml. Incubations were carried out for 60 min at
room temperature. The beads were harvested, washed three times with
phosphate-buffered saline, and resuspended in 25 l of SDS sample
buffer. Bound SRPK1 and SRPK1a were analyzed on 10% SDS-polyacrylamide gels and detected by Western blotting using the M5 antiFLAG monoclonal antibody.
In Vivo Splicing of Human Tau 9-10-11 Minigene—Tau construct
SV9/10/11, containing exon 10 flanked by tau exons 9 and 11, was
described earlier (39). In vivo splicing was performed essentially as
described (40). Briefly, 3 ⫻ 105 HEK293 cells were transfected with 1 g
of the reporter gene together with increasing amounts (0, 0.5, and 1 g)
of plasmid DNA encoding FLAG-SRPK1 or FLAG-SRPK1a, using the
calcium phosphate method. RNA was isolated 17–24 h following transfection, using the RNeasy mini kit (Qiagen), according to the manufacturer’s instructions. Reverse transcription and PCR were carried out as
described previously (40).
FIG. 1. Nucleotide and predicted amino acid sequences of
SRPK1a (EMBL accession number AJ318054). Underlined is the
sequence encoded by the 513-bp insert, and shaded are kinase catalytic
domains. A spacer sequence separates the catalytic domains.
documented that human SRPK1 is mapped to chromosome
6p21.2-p21.3 (41) and the genomic sequence is available
(EMBL data bank, locus HS422H11, accession number Z99128)
we compared the sequence of the isolated clone with the
genomic sequence. The sequence alignment revealed that the
SRPK1 gene comprises 16 exons (Fig. 2A, see also EMBL data
bank, locus HS422H11, accession number Z99128, gene ⫽
dJ422H11.1). The 513-bp insert is located between the first two
exons of SRPK1. This suggests that this segment may be alternatively spliced. The SRPK1 cDNA originally isolated by
40178
Cloning and Characterization of SRPK1a
FIG. 3. Expression of SRPK1a in mammalian cells. Lysates from
293T cells transfected with the pCMV-2 vector alone (control) or with
pCMV-2 vectors encoding FLAG-tagged SRPK1 or SRPK1a were analyzed on 10% SDS-polyacrylamide gels. The proteins were then transferred to nitrocellulose, and epitope-tagged SRPK1 or SRPK1a were
detected with the M5 anti-FLAG monoclonal antibody (A) or the antiSRPK1 polyclonal antibody (B).
Gui et al. (1) would encode the isoform lacking the 171 amino
acids encoded by the 513-bp segment, whereas the novel cDNA,
designated SRPK1a (EMBL data bank, accession number
AJ318054), would encode the isoform containing this sequence
(Fig. 2, A–C). Further analysis revealed the presence of 5⬘- and
3⬘-splice sites at the ends of the intervening regions, suggesting
that the 513-bp segment normally represents an intronic sequence that is not, however, spliced out from the SRPK1a
transcript (Fig. 2D).
The extended NH2-terminal domain of SRPK1a shares no
significant similarity to known proteins and contains a relatively high number of proline residues (Fig. 1B). Yet, unlike
SRPK2, it does not contain the PPLP consensus motif required
for the binding of a subclass of WW domain-containing proteins
(3, 42). Most notably, SRPK1a contains two LXXLL motifs
(148LAPLL152 and 158LGRLL162), which are thought to facilitate the interaction of different proteins with nuclear receptors
(43, 44).
Downloaded from www.jbc.org by guest, on February 19, 2013
FIG. 2. Schematic representation of the alternative splicing of
the 513-bp fragment. A, schematic representation of the SRPK1a/
SRPK1 gene structure. Sequence comparison of AJ318054 and Z99128
revealed the genomic organization of the SRPK1a/SRPK1 gene. Boxes
indicate exons; nucleotide positions in Z99128 are 94672–94651,
94136 –94076, 64621– 64503, 62531– 62423, 61719 – 61632, 60419 –
60332, 47947– 47841, 46336 – 46171, 44567– 44542, 44102– 43889,
43509 – 43090, 42718 – 42621, 30976 –30869, 16212–16143, 12037–
11945, 9096 – 6642 (the genomic sequence is antiparallel to AJ318054).
Exon 1 within the SRPK1a transcript comprises exons 1a and 1b of
SRPK1 as well as the 513-bp segment (nucleotides 94650 –94137),
which is excluded from SRPK1. B, comparison of the amino acid sequence encoded by exon 1 of SRPK1a with the respective sequences
encoded by exons 1a and 1b of SRPK1. The sequence encoded by the
513-bp segment, which is absent in SRPK1, is denoted by the dashed
line. C, the nucleotide sequence surrounding the alternatively spliced
513-bp segment. Splicing out of the 513-bp segment would result in
production of SRPK1 (containing the amino acid sequences encoded by
exons 1a and 1b). Splicing in of the 513-bp segment would result in
production of SRPK1a (containing the amino acid sequence encoded by
the entire exon 1). D, 5⬘- and 3⬘-splice sites found at the boundaries
between exons 1a/1b and the 513-bp segment. The coding sequence in
both SRPK1a and SRPK1 is capitalized, whereas the spliced out sequence (513-bp segment) from SRPK1 is in lowercase letters.
The predicted molecular mass of the kinase encoded by the
SRPK1a cDNA is 92.3 kDa. To detect this protein product, we
tagged the SRPK1a polypeptide with a FLAG epitope and
expressed the fusion protein in 293T cells. As a control we used
FLAG-tagged SRPK1. Extracts from 293T cells transfected
with the pCMV-2 vector alone showed no proteins detected by
anti-FLAG immunoblotting (Fig. 3A, control), whereas extracts
from 293T cells transfected with pCMV-2 vectors encoding
FLAG-tagged SRPK1 or SRPK1a demonstrated immunoreactive proteins of ⬃97 and 92 kDa, respectively (Fig. 3A; note
that, although the predicted molecular mass of SRPK1 is 74.3
kDa, the protein was shown to migrate on SDS-polyacrylamide
gels with an apparent molecular mass of 92–95 kDa; see Refs.
1 and 21). The same bands were also obtained when the immunoblotting was performed with an anti-SRPK1 polyclonal
antibody raised against GST-SRPK1 (Fig. 3B). Only a faint
band of 92 kDa corresponding to FLAG-SRPK1a could be detected when the immunoblotting was performed with a specific
anti-SRPK1a polyclonal antibody raised against GSTSRPK1aNt (the extended NH2-terminal domain of SRPK1a
fused to GST; data not shown).
To demonstrate that SRPK1a cDNA encodes an active protein kinase, we carried out immunoprecipitation experiments.
FLAG-tagged SRPK1 or SRPK1a were transiently transfected
into 293T cells, and the cells were harvested and lysed 48 h
post-transfection. Immunoprecipitations were carried out with
either the M5 anti-FLAG monoclonal antibody or the antiSRPK1 polyclonal antibody or the specific anti-SRPK1a polyclonal antibody. SR protein-kinase activity was assayed on
beads incubated in kinase buffer with bacterially expressed
ASF/SF2 or LBR as substrates and radiolabeled ATP. As
shown in Fig. 4 the anti-FLAG and the anti-SRPK1 antibodies
immunoprecipitated both SRPK1 and SRPK1a, whereas the
specific anti-SRPK1a antibody immunoprecipitated a kinase
activity only from 293T cells transfected with pCMV-2 vector
encoding FLAG-tagged SRPK1a. Interestingly, we reproducibly observed that SRPK1a was 2- to 3-fold more active than
SRPK1. As expected, SRPK1a-mediated phosphorylation took
place in the RS domain, because the immunoprecipitated enzyme was unable to modify a GST fusion protein that contains
the NH2-terminal domain of LBR but lacks the RS motifs
(⌬RSNt, Fig. 4). Furthermore, as previously shown with
SRPK1 (28), SRPK1a efficiently phosphorylated various derivatives of the NH2-terminal domain of LBR fused to GST, in
which Ser78, Ser80, Ser82, and Ser84 of the RS domain
(75RSRSRSRSRS84) were mutated to Gly (wtNtG78), Ala
Cloning and Characterization of SRPK1a
(wtNtA80), Ala (wtNtA82), and Ala (wtNtA84), respectively
(data not shown).
Next, we determined the subcellular localization of FLAGtagged SRPK1 and 1a in transfected COS-1 cells by indirect
immunofluorescence using the M5 anti-FLAG monoclonal antibody. Consistent with previous reports for SRPK1 (2, 3) the
cytoplasmic signal was predominant for both isoforms, although the expressed kinases were also clearly visible in the
nucleus (data not shown). The cytoplasmic and nuclear localization is a characteristic feature of all SRPK family members
and probably reflects a function for these kinases in both compartments. An alternative, although not mutually exclusive,
hypothesis is that the cytoplasmic sequestering of these enzymes may regulate their nuclear functions by controlling their
availability to nuclear substrates.
SR protein kinases affect alternative splicing through a
phosphorylation-mediated release of SR proteins from nuclear
storage sites. In this respect we have previously shown that
SRPK1 was able to regulate the alternative splicing of human
tau exon 10 in transfected cells (45). To determine whether
SRPK1a had an effect similar to that of SRPK1, we tested both
isoforms in co-transfection experiments with the tau minigene
SV9 –10L-11 consisting of exon 10 and its flanking exon and
intron regions (Fig. 5A; see also Ref. 39). Without addition of
SRPK1, exon 10 is skipped in about 25% of the minigenederived RNA, whereas in the presence of SRPK1 or SRPK1a
FIG. 5. Influence of SRPK1a and SRPK1 on alternative splicing of human tau exon 10. A, schematic representation of the expression construct SV9/10L/11. Exon 10 is flanked by tau exons 9 and 11.
Exons 9 and 11 are fused with insulin exons 2 and 3, respectively.
Primers located in these insulin exons were used for amplification.
Thick lines around exon 10 indicate the flanking intronic regions (471
nucleotides downstream, 409 nucleotides upstream). The SV40 promoter is indicated with an arrow. B, HEK293 cells were co-transfected
with 1 g of the SV910L/11 minigene together with increasing amounts
(0, 0.5, and 1 g) of plasmid DNA encoding FLAG-SRPK1 or FLAGSRPK1a. RNA was isolated 17–24 h following transfection, and RTPCR was carried out. The splice products have a size of 336 and 429
nucleotides, respectively. C, statistical evaluation of three independent
experiments. Numbers indicate micrograms of SRPK1 or SRPK1a expression constructs transfected.
this percentage increases to about 50 –70% (Fig. 5B). Consistent with our data from the immunoprecipitation experiments
in transfected cells (see Fig. 4) SRPK1a was more efficient than
SRPK1 in promoting skipping of human tau exon 10.
Thus both isoforms are very similar in terms of substrate
specificity and subcellular localization and in their ability to
induce alternative splicing in transfected cells. It is, however,
unlikely that they are completely redundant kinases, because
they may be differentially expressed and/or regulated. To explore these possibilities we first examined the expression of
both isoforms, by Northern blotting analysis, in multiple human tissues as well as in various human cancer cell lines. In
agreement with our previous report, SRPK1 was predominantly expressed in the testis but was also present at low levels
in most of the tissues examined (Fig. 6A; see also Ref. 27).
SRPK1a was clearly detected only in testis, at a significantly
lower percentage the level of SRPK1 (Fig. 6B). For both isoforms we detected a smaller transcript of 2.7 kb in the testis
(see also Ref. 27).
To further demonstrate that SRPK1a is expressed in testis
we performed reverse transcription coupled with PCR amplification (RT-PCR) to amplify the region encompassing the
513-bp segment of SRPK1a (nucleotide position 1– 658, see Fig.
1) from human testis-derived cDNA. Two DNA species were
amplified, the sizes of which (145 and 658 bp, respectively)
were consistent with alternative splicing of the 513-bp segment
(Fig. 7A). In addition we carried out immunoprecipitation experiments from rat testis cytosol with the specific anti-SRPK1a
polyclonal antibody or the anti-SRPK1 polyclonal antibody. As
shown in Fig. 7B the specific anti-SRPK1a antibody immunoprecipitated a kinase activity that was able to phosphorylate
ASF/SF2 or recombinant LBR but not ⌬RSNt that lacks the RS
Downloaded from www.jbc.org by guest, on February 19, 2013
FIG. 4. SRPK1a cDNA encodes an active protein kinase. 293T
cells were transiently transfected with the pCMV-2 vector alone (control) or with pCMV-2 vectors encoding FLAG-tagged SRPK1 or
SRPK1a. Extracts were prepared at 48 h post-transfection, and immunoprecipitations were carried out with either the M5 anti-FLAG monoclonal antibody or the anti-SRPK1 polyclonal antibody or the specific
anti-SRPK1a polyclonal antibody. The immunoprecipitates were incubated under in vitro phosphorylation conditions with bacterially produced SF2, wtNt (a GST fusion protein containing the NH2-teminal
domain of LBR; amino acids 1–205) and ⌬RSNt (contains the NH2teminal domain of LBR but lacks the RS motifs; amino acids 75– 84).
Labeled proteins were detected by SDS-PAGE and autoradiography.
The full-length wtNt migrates with an apparent molecular mass of ⬃51
kDa. The lower bands represent degradation products (see also Ref. 29).
The gels were exposed for 2 h. Bars on the left indicate molecular
masses (in kDa).
40179
40180
Cloning and Characterization of SRPK1a
FIG. 6. Northern blotting analysis of SRPK1 and SRPK1a. Human multiple tissue I and II Northern blot filters were purchased from
CLONTECH and processed as described under “Materials and Methods.” A cDNA of 860 bp, comprising nucleotides 1– 860 of the sequence
of mouse SRPK1 (EMBL data bank accession number AJ224115; see
also “Materials and Methods” and Ref. 27), and a PCR fragment of 528
bp, comprising nucleotides 1–528 of the coding region of human
SRPK1a, were used as probes for SRPK1 (A) and SRPK1a (B), respectively. Exposure time in B was seven times as long as in A. Positions of
molecular size markers in kilobases, are indicated.
motifs, whereas the anti-SRPK1 antibody immunoprecipitated
a 4-fold higher kinase activity, corresponding to both SRPK1
and SRPK1a. The ratio of SRPK1/SRPK1a, as estimated from
the immunoprecipitation experiment, is lower than the ratio
observed with the RT-PCR and Northern blotting analyses.
This is probably due to the higher activity of SRPK1a as compared with that of SRPK1.
Next, a yeast two-hybrid screen was performed to isolate
proteins that interact specifically with the extended NH2-terminal domain of SRPK1a, because it is well known that interactions through specific protein modules mediate the specificity
of signal transduction events. To this end, SRPK1aNt (encoding amino acids 1–176) was subcloned to pGBT9 in-frame with
the GAL4 DNA binding domain. The yeast strain pJ69-4A
carrying the pGBT9-SRPK1aNt vector was transformed with
an equimolar mixture of E9.5 and E10.5 mouse embryonic
cDNA libraries in which cDNAs were fused to the coding sequence for the VP16 activation domain. Screening of ⬃8 ⫻ 106
recombinant clones led to the isolation of about 80 that grew on
the appropriate selection medium and gave detectable -galactosidase activity. Twenty-one clones remained positive for -galactosidase activity when co-transformed with the SRPK1aNt
fusion protein but not with the DNA binding domain of GAL4
alone. As deduced by DNA sequencing and BLAST searching
three of the positive clones, showing the strongest interaction,
were different isolates of SAF-B, a nuclear scaffold-associated
protein. On the basis of the SAF-B sequences isolated by the
two-hybrid screen, COOH-terminal residues 585–720 (EMBL
data bank accession number AF056324) appear to be sufficient
for the interaction with the NH2-terminal domain of SRPK1a.
Most interestingly, the observed interaction was specific, because all three clones showed a very weak interaction with
SRPK1 when pJ69-4A carrying the clones was co-transformed
with a cDNA, encoding the full-length coding region of SRPK1,
fused to the GAL4 binding domain (Fig. 8).
To confirm the interactions detected in the yeast two-hybrid
assay, we showed that SRPK1a, but not SRPK1, bound
strongly to SAF-B in vitro (Fig. 9A). Purified GST-SAF-B-PC
(containing the COOH-terminal domain of SAF-B, amino acids
493– 874; see also Ref. 32), or GST alone were incubated with
cell extracts from 293T cells transfected with pCMV-2 vectors
encoding either FLAG-tagged SRPK1 or SRPK1a. The complexes were recovered by pull-down with glutathione-Sepharose beads and analyzed by Western blotting with the M5
anti-FLAG monoclonal antibody. The specific interaction of
SRPK1a with SAF-B was also demonstrated in vivo by coimmunoprecipitation/Western blotting analysis (Fig. 9B). To
this end FLAG-tagged SRPK1a or SRPK1 and GFP-tagged
SAF-B-PC were transiently transfected in 293T cells. Complexes between SAF-B and SRPKs were immunoprecipitated
with an anti-GFP monoclonal antibody and separated by SDSPAGE. The proteins were then transferred to nitrocellulose and
epitope-tagged SRPK1a or SRPK1 were detected with the M5
anti-FLAG monoclonal antibody. When FLAG-tagged SRPK1a
was co-transfected with GFP-tagged SAF-B-PC, the 92-kDa
FLAG-SRPK1a polypeptide was detected in the anti-GFP immunoprecipitate (Fig. 9B, last lane), demonstrating a stable
interaction between SAF-B and SRPK1a. When single transfections with FLAG-SRPK1a were carried out, the 92-kDa band
was not obtained in the immunoprecipitates (Fig. 9B, lane 1),
ruling out the possibility that the anti-GFP antibody directly
immunoprecipitated SRPK1a.
These results strongly suggest that one of the SRPK family
members binds specifically to a nuclear scaffold-associated protein. SAF-B has been found phosphorylated in vivo (46). How-
Downloaded from www.jbc.org by guest, on February 19, 2013
FIG. 7. Expression of SRPK1a in human and rat testis. A, RTPCR analysis of SRPK1a/SRPK1 transcripts demonstrates alternative
splicing. Oligonucleotide primers flanking the 513-bp segment were
used to amplify the cDNA generated from human testis total RNA. The
spliced product has a predicted size of 145 bp, whereas the unspliced
product, containing the 513-bp segment, has a predicted size of 658 bp.
A 100-bp DNA ladder is shown on the left. B, SRPK1a or both SRPK1
and SRPK1a were immunoprecipitated from rat testis cytosol with the
specific anti-SRPK1a polyclonal antibody or the anti-SRPK1 polyclonal
antibody, respectively. The immunoprecipitates were incubated under
in vitro phosphorylation conditions with SF2, wtNt, and ⌬RSNt
(SRPK1a only). Labeled proteins were detected by SDS-PAGE and
autoradiography. The gels were exposed for 2 days. Bars on the left
indicate molecular masses (in kDa).
Cloning and Characterization of SRPK1a
40181
containing proteins, which are in close vicinity with the nuclear
scaffold, may be preferentially targeted by this kinase isoform.
DISCUSSION
FIG. 8. The NH2-terminal domain of SRPK1a interacts with
SAF-B in yeast. S. cerevisiae strain pJ69-4A was co-transformed with
(A) pGBT9-SRPK1aNt and pVP16, (B) pGBT9-SRPK1aNt and pVP16SAF-B, (C) pGBT9 and pVP16-SAF-B, (D) pGBT9- SRPK1 and pVP16,
(E) pGBT9-SRPK1 and pVP16-SAF-B, and (F) pGBT9 and pVP16. The
strains were streaked in the same order on plates containing SC minus
Trp, Leu, Ade, His, and 3 mM AT (left) or SC minus Trp, Leu, Ade, His,
and 100 mM AT (right). The SAF-B clone used in these experiments
encodes amino acids 585–720 of rodent SAF-B (EMBL data bank accession number AF056324).
ever, this protein is not a potential substrate of the SRPKs,
because it does not contain any alternating RS or SR dipeptides. Indeed, we have been unable to detect any phosphorylation of GST-SAF-B-PC by immunoprecipitated FLAG-tagged
SRPK1a or bacterially expressed GST-SRPK1 (data not
shown). This implies that SAF-B acts as a “docking site” rather
than as a substrate for SRPK1a and thereby, RS domain-
Downloaded from www.jbc.org by guest, on February 19, 2013
FIG. 9. Interaction between SRPK1a and SAF-B in vitro and in
mammalian cells. A, GST-SAF-B-PC or GST alone, as a negative
control, were incubated with cell extracts from 293T cells transfected
with pCMV-2 vectors encoding either FLAG-tagged SRPK1a or SRPK1.
The complexes were recovered by pull-down with glutathione-Sepharose beads and analyzed on 10% SDS-polyacrylamide gels. Bound
SRPK1a or SRPK1 were detected by Western blotting using the M5
anti-FLAG monoclonal antibody. A standard amount of cell extract,
one-third of which is shown (lanes 1 and 4), was used in each binding
assay. B, 293T cells were co-transfected with plasmids expressing
FLAG-tagged SRPK1a or SRPK1 and GFP-tagged SAF-B-PC. Complexes between SAF-B and SRPKs were immunoprecipitated with an
anti-GFP monoclonal antibody and analyzed on 10% SDS-polyacrylamide gels. The proteins were then transferred to nitrocellulose, and
epitope-tagged SRPK1a or SRPK1 were detected with the M5 antiFLAG monoclonal antibody. No direct immunoprecipitation of FLAGtagged SRPK1a by the anti-GFP antibody was observed (lane 1).
We report here the cloning and characterization of a third
member of the SRPK family of protein kinases, which is an
alternatively spliced form of SRPK1, named SRPK1a. The
SRPK1/SRPK1a locus is situated on human chromosome 6.
Splicing out of a 513-bp segment, which is located between
exons 1a and 1b, would result in the production of SRPK1,
whereas splicing in of the 513-bp segment would yield SRPK1a
(see Fig. 2). In the latter case a large exon 1 is assembled within
the SRPK1a transcript that comprises exons 1a and 1b of
SRPK1 as well as the 513-bp segment.
Probably, SRPK1a does not represent the only paradigm of
SR protein kinase regulation at the pre-mRNA processing
level. Bedford et al. (47) identified a partial mouse cDNA clone,
WBP6 (WW-domain binding protein 6; accession number
U92456), based on its binding to a WW domain-containing
protein probe in an expression screen. The nucleotide sequence
of this clone is identical to mouse SRPK2 with the exception of
an additional NH2-terminal sequence in WBP6. Although further studies are required, this suggests that WBP6 may be an
alternatively spliced SRPK2 product found in the mouse. Furthermore, two more isoforms encoded by the SRPK1 gene, each
containing a different exon 14, have been predicted by the
Sanger Center (locus HS422H11, accession number Z99128,
gene products dJ422H11.1.1 and dJ422H11.1.2). Exon 14 encodes the amino acid sequence between catalytic subdomains X
and XI (catalytic subdomains are indicated analytically in Ref.
1). Even though the existence of those isoforms is not experimentally documented, our data, supported by the above prediction, raise the intriguing possibility that four different isoforms may arise from a single SRPK1 gene.
Several isoforms of the ubiquitous LAMMER protein kinase
family (named upon the existence of the motif EHLAMMERILG in their catalytic sub-domain X), which also target SR
proteins and affect splicing (13), have also been identified. Both
mouse CLK1 and the Drosophila homologue doa give rise to
transcripts coding for either the full-length catalytically active
kinase or a truncated protein lacking the catalytic domain (48,
49). Identical splice forms were also found in human homologues (50). The ratio of these splice products appears to be
regulated developmentally in Drosophila (48) and in a tissue
and cell-specific manner in mammals (49, 50). In addition, in
adult mouse tissues or upon stem cell differentiation, larger
transcripts, representing partially spliced products that are
sequestered in the nucleus and are unavailable for protein
translation, were also detected (49, 51).
SRPK1a expressed in mammalian cells was highly active
and showed the same substrate specificity as SRPK1. Both
isoforms were able to induce alternative splicing of human tau
exon 10 in transfected cells. Furthermore, they were similarly
expressed in various human tissues, although the level of expression of SRPK1a was significantly lower than that of
SRPK1. Despite their high similarity, these two SRPK family
members probably exert distinct cellular functions through
differential targeting. Using the yeast two-hybrid assay we
found that the NH2-terminal domain of SRPK1a interacts with
SAF-B, implying that this isoform is associated with the nuclear matrix. An SAF-B fusion protein can extract SRPK1a but
practically no SRPK1 from cell lysates, and antibodies that
immunoprecipitate SAF-B can specifically co-precipitate
SRPK1a, further confirming the specificity of this interaction.
Furthermore, two of the isolated clones in our two-hybrid
screen encoded overlapping parts of lamin B. Although this
interaction has not yet been ascertained by binding experi-
40182
Cloning and Characterization of SRPK1a
Acknowledgments—We thank J. Tazi for providing us with recombinant ASF/SF2, G. Mosialos for the M5 anti-FLAG monoclonal antibody,
G. Chalepakis for the mouse embryonic cDNA library, Andrea Andreadis
for the SV9/10/11, and A. Mungall, on behalf of the Sanger Center, for
the PAC 422H11 genomic clone. We also thank L. Papadopoulou for
RT-PCR analysis, A. Tsiftsoglou for providing us with tissue culture
facility, S. Bonanou for her constant support, and S. D. Georgatos and
J. G. Georgatsos for useful discussions and comments on the manuscript.
REFERENCES
1. Gui, J.-F., Lane, W. S., and Fu, X.-D. (1994) Nature 369, 678 – 682
2. Gui, J.-F., Tronchere, H., Chandler, S. D., and Fu, X.-D. (1994) Proc. Natl.
Acad. Sci. U. S. A. 91, 10824 –10828
3. Wang, H.-Y, Lin, W., Dyck, J. A., Yeakley, J. M., Songyang, Z., Cantley, L. C.,
and Fu, X.-D. (1998) J. Cell Biol. 140, 737–750
4. Kuroyanagi, N., Onogi, H., Wakabayashi, T., and Hagiwara, M. (1998) Biochem. Biophys. Res. Commun. 242, 357–364
5. Fu, X.-D. (1995) RNA (N. Y.) 1, 663– 680
6. Manley, J. L., and Tacke, R. (1996) Genes Dev. 10, 1569 –1579
7. Valcarcel, J., and Green, M. R. (1996) Trends Biochem. Sci. 21, 296 –301
8. Fu, X.-D. (1993) Nature 365, 82– 85
9. Kohtz, J. D., Jamison, S. F., Will, C. L., Zuo, P., Luhrmann, R., Garcia-Blanco,
M. A., and Manley, J. L. (1994) Nature 368, 119 –124
10. Tarn, W. Y., and Steitz, J. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92,
2504 –2508
11. Valcárcel, J., Gaur, R. K., Singh, R., and Green, M. R. (1996) Science 273,
1706 –1709
12. Xiao, S. H., and Manley, J. L. (1997) Genes Dev. 11, 334 –344
13. Colwill, K., Pawson, T., Andrews, B., Prasad, J., Manley, J. L., Bell, J. C., and
Duncan, P. I. (1996) EMBO J. 15, 265–275
14. Misteli, T., Caseres, J. F., and Spector, D. L. (1997) Nature 387, 523–527
15. Misteli, T., Caseres, J. F., Clement, J. Q., Krainer, A. R., Wilkinson, M. F., and
Spector, D. L. (1998) J. Cell Biol. 143, 297–307
16. Mayeda, A., and Krainer, A. R. (1992) Cell 68, 365–375
17. Zahler, A. M., Neugebauer, K. M., Lane, W. S., and Roth, M. B. (1993) Science
260, 219 –222
18. Caceres, J. F., Stamm, S., Helfman, D. M., and Krainer, A. R. (1994) Science
265, 1706 –1709
19. Screaton, G. R., Caceres, J. F., Mayeda, A., Bell, M. V., Plebanski, M., Jackson,
D. G., Bell, J. I., and Krainer, A. R. (1995) EMBO J. 14, 4336 – 4349
20. Wang, J., and Manley, J. L. (1995) RNA (N. Y.) 1, 335–346
21. Koizumi, J., Okamoto, Y., Onogi, H., Mayeda, A., Krainer, A. R., and
Hagiwara, M. (1999) J. Biol. Chem. 274, 11125–11131
22. Takeuchi, M., and Yanagida, M. (1993) Mol. Biol. Cell 4, 247–260
23. Siebel, C. W., Feng, L., Guthrie, C., and Fu, X.-D. (1999) Proc. Natl. Acad. Sci.
U. S. A. 96, 5440 –5445
24. Yun, C. Y., and Fu, X.-D. (2000) J. Cell Biol. 150, 707–717
25. Erez, O., and Kahana, C. (2001) Mol. Cell. Biol. 21, 175–184
26. Kuroyanagi, H., Kimura, T., Kazuhiro, W., Hisamoto, N., Matsumoto, K., and
Hagiwara, M. (2000) Mech. Dev. 99, 51– 64
27. Papoutsopoulou, S., Nikolakaki, E., Chalepakis, G., Kruft, V., Chevaillier, P.
and Giannakouros, T. (1999) Nucleic Acids Res. 27, 2972–2980
28. Papoutsopoulou, S., Nikolakaki, E., and Giannakouros, T. (1999) Biochem.
Biophys. Res. Commun. 255, 602– 607
29. Nikolakaki, E., Simos, G., Georgatos, S. D., and Giannakouros, T. (1996)
J. Biol. Chem. 271, 8365– 8372
30. Bode, J., Benham, C., Knopp, A., and Mielke, C. (2000) Crit. Rev. Eukaryot.
Gene Expr. 10, 73–90
31. Maniatis, T., Fritsch, E. F., and Sambrook, J. (1982) Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor,
NY
32. Nayler, O., Stratling, W., Bourquin, J. P., Stagljar, I., Lindemann, L., Jasper,
H., Hartmann, A. M., Fackelmayer, F. O., Ullrich, A., and Stamm, S. (1998)
Nucleic Acids Res. 26, 3542–3549
33. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY
34. James, P., Halladay, J., and Craig, E. A. (1996) Genetics 144, 1425–1436
35. Hollenberg, S. M., Sternglanz, R., Feng Cheng, P., and Weintraub, H. (1995)
Mol. Cell. Biol. 15, 3813–3822
36. Rose, M. D., Winston, F., and Hieter, P. (1990) Methods in Yeast Genetics, Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY
37. Chen, C., and Okayama, H. (1997) Mol. Cell. Biol. 7, 2745–2752
38. Bradford, M. M. (1976) Anal. Biochem. 72, 248 –254
39. Gao, Q. S., Memmott, J., Lafyatis, R., Stamm, S., Screaton, G., and Andreadis,
A. (2000) J. Neurochem. 74, 490 –500
40. Stoss, O., Stoilov, P., Hartmann, A. M., Nayler, O., and Stamm, S. (1999) Brain
Res. Prot. 4, 383–394
41. Wang, H.-Y., Arden, K. C., Bermingham, J. R., Viars, C. S., Lin, W., Boyer,
A. D., and Fu, X.-D. (1999) Genomics 57, 310 –315
42. Sudol, M. (1996) Prog. Biophys. Mol. Biol. 65, 113–132
43. Torchia, J., Rose, D. W., Inostroza, J., Kamel, Y., Westin, S., Glass, C. K., and
Rosenfeld, M. G. (1997) Nature 387, 677– 684
44. Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997) Nature 387,
733–736
45. Hartmann, A. M., Rujescu, D., Giannakouros, T., Nikolakaki, E., Goedert, M.,
Mandelkow, E., Gao, Q. S., Andreadis, A., and Stamm, S. (2001) Mol. Cell.
Neurosci. 18, 80 –90
46. Renz, A., and Fackelmayer, F. O. (1996) Nucleic Acids Res. 24, 843– 849
47. Bedford, M. T., Chan, D. C., and Leder P. (1997) EMBO J. 16, 2376 –2383
48. Yun, B., Farkas, R., Lee, K., and Rabinow, L. (1994) Genes Dev. 8, 1160 –1173
49. Duncan, P. I., Howell, B. W., Marius, R. M., Drmanic, S., Douville, E. M. J.,
and Bell, J. C. (1995) J. Biol. Chem. 270, 21524 –21531
50. Hanes, J., von der Krammer, H., Klaudiny, J., and Scheit, K. H. (1994) J. Mol.
Biol. 244, 665– 672
51. Ben-David, Y., Letwin, K., Tannock, L., Bernstein, A., and Pawson, T. (1991)
EMBO J. 10, 317–325
52. Luderus, M., de Graaf, A., Mattia, E., der Blaauwen, J., Grande, M., Jong, L.,
and von Driel, R. (1992) Cell 70, 949 –959
53. Blencowe, B. J., Nickerson, J. A., Issner, R., Penman, S., and Sharp, P. A.
(1994) J. Cell Biol. 127, 593– 607
54. Blencowe, B. J., Bauren, G., Eldridge, A. G., Issner, R., Nickerson, J. A.,
Rosonina, E., and Sharp, P. A. (2000) RNA (N. Y.) 6, 111–120
55. Oesterreich, S., Lee, A. V., Sullivan, T. M., Samuel, S. K., Davie J. R., and
Fuqua, S. A. W. (1997) J. Cell. Biochem. 67, 275–286
56. Arao, Y., Kuriyama, R., Kayama, F., and Kato, S. (2000) Arch. Biochem.
Biophys. 380, 228 –236
57. Weighardt, F., Cobianchi, F., Cartegni, L., Chiodi, I., Villa, A., Riva, S., and
Biamonti, G. (1999) J. Cell Sci. 112, 1465–1476
Downloaded from www.jbc.org by guest, on February 19, 2013
ments, it is interesting to note that lamins and other proteins
containing coiled-coiled ␣-helices have also been found to interact with S/MAR DNA sequences (52).
An immunofluorescence analysis of the intracellular localization of SRPK1a did not indicate a localization within the
nucleus, similar to that observed for SAF-B (32). On the contrary, the cytoplasmic localization of the kinase was predominant. Although the subcellular localization of SRPK1a in interphase cells does not, therefore, support the co-localization of
SRPK1a and SAF-B, it has been suggested that the cytoplasmic
sequestering of all SRPK family members, mediated by a nonconserved spacer sequence that separates the conserved catalytic kinase domains, may regulate their nuclear functions by
controlling their nuclear concentration (22, 23). Thus only a
specific fraction of each kinase enters the nucleus, which then
may have a distinct subnuclear localization.
Several nuclear matrix proteins were found to interact with
members of the splicing machinery and function to the recognition and sequestration of exon sequences during the processing of pre-mRNA (53, 54). Furthermore, a number of recent
reports established the existence of macromolecular complexes
containing transcriptional and pre-mRNA processing proteins
(see Ref. 32 and references therein). SAF-B has been implicated
both in transcription (32, 55, 56) and splicing (32, 57). Recently
it has been considered as a molecular base where a “transcriptosome complex” could be assembled, in the vicinity of actively
transcribed genes (32). Most interestingly, although SAF-B
does not contain any alternate RS dipeptides and, therefore, is
not a substrate for the SRPKs, it contains a region rich in
glutamic acid/arginine repeats (amino acids 585– 658), which
was part of our yeast two-hybrid clones. The presence of alternating positive and negative residues in this domain is reminiscent of similar dipeptide motifs found in phosphorylated SR
domains and might be critical for protein-protein interactions.
SRPK1a may therefore utilize SAF-B as a docking site to
phosphorylate splicing factors and other RS domain-containing
proteins, that are in close vicinity with the nuclear matrix.
Phosphorylation of these proteins may not only be critical to
their function but also regulate their interaction with the nuclear matrix. Along these lines we noticed that phosphorylation
of five polypeptides, with apparent molecular masses of 29, 36,
50, 80, and 190 kDa, respectively, that co-precipitate with
SAF-B, was significantly increased when SRPK1a was overexpressed in 293T cells (data not shown). The identity of those
proteins remains unknown at present.
Taken together our data support the concept that mammalian cells have evolved multiple SR protein kinases that are
uniquely regulated and targeted. Thus, although various SRPKs show the same substrate specificity, they may perform specialized cellular functions. The identification of additional SRPK
family members, together with the delineation of their regulation
pathways and the identification and characterization of additional substrates, specifically modified by them, will ultimately
contribute to an understanding of the functions of these enzymes.